Apo-Acyclovir Tablets: NDMA impurity
Last updated
Summary
Product
Apo-Acyclovir Tablets
Issue
Health products - Contamination
What to do
Continue taking your medication unless you have been advised to stop by your health care provider. You do not need to return your medication to your pharmacy. Not treating your condition may pose a greater health risk.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
Apotex |
Apo-Acyclovir 200mg |
DIN 02207621 |
Tablet |
Acyclovir 200mg |
RH9370, RH9368 |
Apotex |
Apo-Acyclovir 800mg |
DIN 02207656 |
Tablet |
Acyclovir 800mg |
RT8943, RP8516, RP8517 |
Issue
Affected lot exceeds concentration limit for N-nitrosodimethylamine (NDMA).
What you should do
- Continue taking your medication unless you have been advised to stop by your health care provider. You do not need to return your medication to your pharmacy. Not treating your condition may pose a greater health risk.
- Talk to your health care provider if you are taking a recalled product and are concerned about your health.
- If you have questions about the recall, contact Apotex Inc. at 1-888-628-0732 or by email at apotex4315@sedgwick.com.
- Report any health product-related side effects or complaints to Health Canada.
Additional information
Previous recalls or alerts
Background
Depth of recall: Retailers, Wholesalers, Healthcare establishments.
Details
Original published date: 2022-04-28
Alert / recall type
Health product recall
Category
Health product - Drugs
Companies
|
Apotex Inc. 150 Signet Drive, Toronto, Ontario, M9L 1T9 |
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type I
Identification number
RA-64118
History
Change log
2022-07-28: New lot numbers added